大行評級 | 交銀:阿裏改爲香港主要上市或可納入港股通,評級“買入”
格隆匯7月27日丨交銀國際發報告表示,阿裏巴巴(9988.HK)向港交所申請香港爲主要上市地,有助於擴大投資者規模、提升流動性,且有望納入港股通。另外,根據最新《合夥協議》,今年5月31日起集團關聯方不再擔任合夥人,年報披露目前阿裏共29位合夥人,螞蟻管理層退出,協議修訂提升螞蟻集團管理獨立性。該行維持阿裏巴巴“買入”評級,美股目標價162美元,港股目標價爲156港元。該股現報100.8港元,總市值21860億港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.